Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease.
Paul Wei-Che Hsu, Chi-Hsiao Yeh, Chi-Jen Lo...
https://pubmed.ncbi.nlm.nih.gov/40830908Actively Recruiting
Age: 20Years +
All Genders
ID07248371
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases: A Step Towards Precision Medicine
Led by Chang Gung Memorial Hospital · Updated on 2025-11-25
6266
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating integrative multi-omics approaches to better understand complications related to metabolic syndrome. The study aims to identify biological factors that predict disease progression by combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome. This research seeks to support precision prevention and treatment strategies for metabolic disorders. This longitudinal, multi-center observational study will recruit individuals diagnosed with metabolic syndrome as well as age- and sex-matched controls without the condition. Participants will provide annual blood, urine, and stool samples for comprehensive profiling including DNA sequencing, RNA sequencing, metabolite analysis, and stool microbiota assessment. These biological samples will be linked with clinical data from a research database to create a unified framework for integrative analysis. Participants will be followed for up to five years, during which researchers will collect biological samples and clinical information annually. The study will use advanced bioinformatics and machine learning tools to identify molecular networks and biomarkers associated with metabolic complications such as cardiovascular disease, chronic kidney disease, and fatty liver disease. Data will be securely stored with participant confidentiality maintained. The main outcome is the identification and validation of multi-omics biomarkers related to metabolic syndrome and its complications over a five-year period.
CONDITIONS
Brief Title
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases
Who Can Participate
Age: 20Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Individuals (male or female) aged 20 years or older
- Willing and able to provide written informed consent to participate in the study
You will not qualify if you...
- Pregnant or breastfeeding women
- Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis
- Individuals currently undergoing active cancer treatment
- Recipients of any organ transplantation
- Patients diagnosed with dementia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 5 years
Participants provide annual blood, urine, and stool samples for multi-omics profiling and are observed through longitudinal clinical follow-up to identify molecular signatures associated with metabolic syndrome and its complications.
Annual visits for biospecimen collection
Trial Site Locations
Total: 1 location
1
Chang Gung Memorial Hospitals, Linkou
Taoyuan, Taiwan
Actively Recruiting
Loading map...
Research Team
C
Chi-Hsiao Yeh, MD PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here